Merit Medical Systems (MMSI) Projected to Post Earnings on Thursday

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) is expected to be releasing its earnings data after the market closes on Thursday, April 24th. Analysts expect Merit Medical Systems to post earnings of $0.75 per share and revenue of $352.57 million for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.

Merit Medical Systems Stock Performance

NASDAQ MMSI traded up $0.32 on Friday, hitting $90.89. 627,778 shares of the stock were exchanged, compared to its average volume of 485,738. The company has a market capitalization of $5.37 billion, a PE ratio of 44.55, a P/E/G ratio of 2.34 and a beta of 0.85. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82. The business's fifty day moving average is $100.15 and its 200 day moving average is $100.62. Merit Medical Systems has a 52 week low of $71.57 and a 52 week high of $111.45.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MMSI. JPMorgan Chase & Co. assumed coverage on shares of Merit Medical Systems in a report on Friday, March 28th. They issued an "overweight" rating and a $120.00 target price on the stock. Wells Fargo & Company cut their price objective on Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Piper Sandler reissued an "overweight" rating and set a $116.00 target price (up from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Raymond James raised their price target on Merit Medical Systems from $105.00 to $110.00 and gave the company an "outperform" rating in a report on Tuesday, December 31st. Finally, Canaccord Genuity Group decreased their price objective on shares of Merit Medical Systems from $128.00 to $127.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $114.33.

Insider Transactions at Merit Medical Systems

In other Merit Medical Systems news, insider Brian G. Lloyd sold 30,000 shares of Merit Medical Systems stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $102.90, for a total value of $3,087,000.00. Following the completion of the sale, the insider now owns 38,945 shares in the company, valued at $4,007,440.50. The trade was a 43.51 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Fred P. Lampropoulos sold 31,320 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the transaction, the chief executive officer now owns 1,086,028 shares in the company, valued at approximately $112,794,868.08. The trade was a 2.80 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,132 shares of company stock valued at $11,139,521. 3.70% of the stock is currently owned by corporate insiders.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.